AKT1 and cancer: To determine whether ALM, a novel compound down-regulates AKT and mTOR activity, can improve anti-cancer efficiency of mTOR inhibitors, we performed experiment to evaluate the effect of ALM in the combination therapy with rapamycin (the classic mTOR inhibitor) or Everolimus.